Notably, This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.

Executive Summary
Moreover, autoimmune diseases collectively represent the second-largest therapeutic area after oncology, with 5,533 active drug programs across the disease cluster, 11,570 patent filings since January 2023, and over a million ongoing clinical trials when aggregated across the major indications (lupus, rheumatoid arthritis, multiple sclerosis, psoriasis, IBD, myasthenia gravis, and others). Notably, 2025-2026 produced a transformational regulatory wave: Anbalcabtagene autoleucel and Puzolcabtagene Autoleucel — the first CAR-T therapies approved for autoimmune indications — alongside oral peptide IL-23 (Icotrokinra), BTK inhibitors for multiple sclerosis (Tolebrutinib, Remibrutinib), APRIL antagonist for IgA nephropathy (Sibeprenlimab), and complement inhibitors (Narsoplimab).
Specifically, the late-stage competitive frontier is segmenting into four strategic lanes: (1) cytokine-targeted biologics dominated by AbbVie’s Skyrizi/Rinvoq, Janssen’s Tremfya/Stelara/Icotrokinra, and Sanofi’s Dupixent across multiple indications; (2) BTK inhibitors led by Sanofi’s Tolebrutinib and Novartis’s Remibrutinib establishing a new oral mechanism for MS, MG, and chronic spontaneous urticaria; (3) CAR-T cell therapy reframing severe autoimmune disease as a curative-intent indication; and (4) emerging modalities including molecular glues, hypoimmune cell therapy (Sana), and retroelement-targeting platforms (Rome Therapeutics).
However, the strategic outlook is increasingly defined by mechanism diversification rather than incremental cytokine blockade. As a result, B-cell-depleting CAR-T, BTK, and APRIL antagonists represent the most active growth vectors. Furthermore, Chinese players including Hengrui, Akeso, and emerging biotech filers have dramatically increased patent activity, signaling that the next wave of autoimmune competition will increasingly originate from Asian pipelines.
Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated — from extracting molecules to mapping competitive pipelines — into a structured output like the report below.
Arena Overview
Pipeline by Modality
Across the 200+ sampled autoimmune programs, small molecules dominate with 105 entries (oral BTK, JAK, TYK2, S1P, PDE4 modulators), followed by 47 monoclonal antibodies, 5 autologous CAR-T programs, 5 synthetic peptides, 4 bispecific T-cell engagers, 4 Fc fusion proteins, 3 cyclic peptides, 3 non-degrading molecular glues, 2 Fc fragments, and 2 fecal microbiota transplantation programs. Notably, the rise of CAR-T (5 programs, 2 already approved in 2025-2026) and BiTEs (4 programs) signals that hematology cell-therapy modalities are migrating into severe autoimmune disease. Moreover, the molecular glue and Fc-fragment entries indicate that next-generation oral biologics — bridging small molecules and antibodies — are entering preclinical development.
Patent Filing Activity
However, patent activity since 2023 reflects intense innovation across modality classes. Specifically, Jiangsu Hengrui Medicine and Shanghai Hengrui Pharm each lead with 7 filings (14 combined under the Hengrui umbrella), followed by Rome Therapeutics at 4, Biogen and Sitryx Therapeutics at 3 each, then Shanghai Haiyan Pharma Tech, Yangtze River, Hainan Simcere, Calico Life Sci, AbbVie, BeneThera Beijing, and Bristol Myers Squibb each at 2. Importantly, the assignee mix combines big pharma (Biogen, AbbVie, BMS), Chinese platforms (Hengrui, Yangtze, Simcere, BeneThera), and novel-mechanism specialists (Rome Therapeutics for retroelement biology, Sitryx for immunometabolism, Calico for aging-related immunity) — a structural signal that autoimmune diseases will see continued mechanistic experimentation through 2027.
Player Summary Table
| Player | Region | Tier | Lead Products | Key Evidence |
|---|---|---|---|---|
| AbbVie | US | Tier 1 — Leader | Skyrizi, Rinvoq, Humira biosimilars | Multi-indication autoimmune leader |
| Janssen (J&J) | US/Belgium | Tier 1 — Leader | Stelara, Tremfya, Icotrokinra | IL-23 portfolio across PsO/PsA/IBD |
| Sanofi | France | Tier 1 — Leader | Dupixent, Tolebrutinib | Atopic / asthma + MS BTK |
| Roche / Genentech | Switzerland/US | Tier 1 — Leader | Ocrelizumab, Rituximab biosimilars | MS / RA B-cell depletion |
| Novartis | Switzerland | Tier 1 — Leader | Cosentyx, Remibrutinib | IL-17 + BTK |
| Eli Lilly | US | Tier 1 — Leader | Taltz, Mirikizumab, Olumiant | Multi-indication immunology |
| Biogen | US | Tier 2 — Active | MS portfolio, autoimmune pipeline | 3 patents 2023+ |
| Bristol Myers Squibb | US | Tier 2 — Active | Sotyktu, Zeposia | Oral TYK2 + S1P |
| UCB | Belgium | Tier 2 — Active | Bimzelx | Dual IL-17A/F |
| Hengrui (Jiangsu + Shanghai) | China | Tier 2 — Active | Ivarmacitinib, Jaktinib + multiple oral mAbs | 14 patents 2023+ |
| Akeso | China | Tier 2 — Active | Ebdarokimab + multiple bispecifics | NMPA approvals across indications |
| Sana Biotechnology | US | Tier 3 — Emerging | Hypoimmune CD19 / CD38 CAR-T | 2 patents 2023+; lupus and MS programs |
| Rome Therapeutics | US | Tier 3 — Emerging | Retroelement-targeted molecules | 4 patents 2023+; novel mechanism |
| Sitryx Therapeutics | UK | Tier 3 — Emerging | Immunometabolism modulators | 3 patents 2023+ |
| Calico Life Sciences | US | Tier 3 — Emerging | Aging-related immune modulators | 2 patents 2023+ |
| Cabaletta Bio | US | Tier 3 — Emerging | CABA-201 CAR-T | Autoimmune CAR-T platform |
Generate Competitive Landscape Reports Like This — in Minutes
Powered by Eureka LS AI
- ✔ Analyze patents, literature, and pipelines together
- ✔ Extract molecule & SAR data automatically
- ✔ Compare competitors and identify key assets
- ✔ Get structured reports instantly
Route Differentiation Analysis
| Route | Tier 1 Leaders | Tier 2 Active | Tier 3 Emerging | Strategic Position |
|---|---|---|---|---|
| Cytokine-targeted mAb (IL-17, IL-23, IL-4/13) | AbbVie, Janssen, Sanofi, Lilly, Novartis, UCB | Akeso, Hengrui | Multiple biosimilars | Saturated — biosimilar transition |
| BTK inhibitor (oral) | Sanofi (Tolebrutinib), Novartis (Remibrutinib) | Multiple second-gen programs | Several preclinical | Differentiated — fast-growing |
| JAK / TYK2 oral inhibitor | AbbVie (Upadacitinib), BMS (Deucravacitinib) | Pfizer, Hengrui, Reistone | Multiple Chinese filers | Active — black-box-warning constrained |
| S1P modulator | Pfizer (Etrasimod), BMS (Ozanimod) | Multiple second-gen programs | Several preclinical | Differentiated — third oral mechanism |
| Autologous CAR-T (B-cell depletion) | — | Cabaletta, Anbalcabtagene, Puzolcabtagene | Multiple academic / Chinese | Differentiated — curative intent |
| Allogeneic / hypoimmune CAR-T | — | Sana Biotechnology | Multiple platforms | Emerging — high reward |
| FcRn antagonist | argenx (Efgartigimod), UCB (Rozanolixizumab) | Multiple follow-ons | Multiple Chinese filers | Active — myasthenia and IgG-mediated AI |
| APRIL / BAFF antagonist | Sibeprenlimab | Multiple second-gen programs | Several preclinical | Emerging — IgA nephropathy |
| Retroelement / immunometabolism / molecular glue | — | Rome Therapeutics, Sitryx, Calico | Multiple platform companies | Emerging — novel-mechanism experimentation |
Route Concentration Observations
- Notably, BTK inhibitors have emerged as the most strategically active route in 2025-2026, with two FDA approvals (Tolebrutinib for MS, Remibrutinib for chronic urticaria) and broad indication expansion.
- Moreover, autoimmune CAR-T has crossed the credibility threshold with two NMPA approvals (Anbalcabtagene autoleucel, Puzolcabtagene autoleucel), though Western regulatory pathways are still being established.
- However, FcRn antagonism (Efgartigimod, Rozanolixizumab) has expanded faster than expected, capturing IgG-mediated autoimmune indications including myasthenia gravis, ITP, and pemphigus.
- In addition, novel-mechanism platforms — retroelement biology (Rome), immunometabolism (Sitryx), aging-related immune modulators (Calico) — represent the long-tail experimentation that could reframe autoimmunity by 2030.
Top Player Deep Dives
AbbVie (Skyrizi + Rinvoq)
Primary route: In addition, anti-IL-23p19 mAb (Skyrizi) plus oral selective JAK1 inhibitor (Rinvoq), spanning psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease, atopic dermatitis, rheumatoid arthritis, and ankylosing spondylitis. Specifically, AbbVie has the broadest multi-indication immunology franchise.
Key pipeline: As a result, skyrizi and Rinvoq remain core; AbbVie also has 2 patents 2023+ across novel autoimmune mechanisms. Moreover, Humira biosimilar revenue continues to support continued investment in the pipeline.
Differentiation: Specifically, multi-indication labels and dual-modality positioning (biologic + oral) provide AbbVie with the largest commercial scale of any single immunology player. As a result, AbbVie is the single most commercially important autoimmune pharma globally.
Recent BD: Meanwhile, abbVie continues to invest internally in immunology; no major outbound BD recently.
Trajectory: In contrast, skyrizi and Rinvoq remain on track to be major franchise contributors. Consequently, lifecycle strategies focus on label expansion and combination approaches.
Key risk: Similarly, biosimilar entry post-LOE in late 2030s; near-term threat from oral peptide alternatives like Icotrokinra capturing convenience-driven segments.
Sanofi (Dupixent + Tolebrutinib)
Primary route: Furthermore, anti-IL-4Rα (Dupixent) for atopic dermatitis, asthma, EoE, prurigo nodularis, and chronic rhinosinusitis with nasal polyps; oral BTK inhibitor (Tolebrutinib) for multiple sclerosis. Specifically, Sanofi spans Th2-driven and B-cell-driven autoimmunity.
Key pipeline: Additionally, dupixent expands across IL-4/13-driven indications; Tolebrutinib received FDA approval in August 2025 for relapsing MS. Moreover, Sanofi has emerging anti-CD40L and other autoimmune programs.
Differentiation: Importantly, dupixent’s Th2-pathway breadth provides multi-indication revenue depth; Tolebrutinib’s CNS-penetrant BTK profile is uniquely positioned for MS. Furthermore, Sanofi has positioned the BTK molecule for both relapsing and progressive MS.
Recent BD: Overall, tolebrutinib was acquired through Principia Biopharma in 2020 ($3.7B); Dupixent was developed under the Regeneron alliance.
Trajectory: Indeed, dupixent remains a multi-billion franchise with continued indication expansion; Tolebrutinib launch dynamics in MS will be closely watched in 2026-2027.
Key risk: Consequently, dupixent biosimilar erosion post-LOE; Tolebrutinib hepatotoxicity signal that delayed earlier US approval may constrain prescribing.
Sana Biotechnology / Cabaletta (Autoimmune CAR-T)
Primary route: Therefore, allogeneic hypoimmune CAR-T (Sana SC-DARIC38) and autologous CD19 CAR-T (Cabaletta CABA-201) for severe autoimmune diseases including lupus, myositis, and systemic sclerosis. Specifically, B-cell depletion via CAR-T provides curative-intent therapy for refractory autoimmune disease.
Key pipeline: In particular, sana’s hypoimmune platform extends to CD38 and CD19; Cabaletta’s CABA-201 is in Phase 1/2 for multiple autoimmune indications. Moreover, multiple Chinese players have CAR-T autoimmune programs in development.
Differentiation: Likewise, curative-intent CAR-T positioning could transform refractory autoimmune disease economics by enabling one-time treatment instead of chronic biologics. Furthermore, Sana’s hypoimmune approach could eliminate lymphodepletion and enable ambulatory CAR-T administration.
Recent BD: Thus, multiple CAR-T autoimmune deals are in early-stage discussions; specific terms are not yet disclosed.
Trajectory: For example, phase 1/2 readouts in 2025-2026 will determine whether autoimmune CAR-T moves from exceptional case reports to scalable therapy. As a result, this is one of the highest-reward, highest-risk autoimmune routes.
Key risk: At the same time, lymphodepletion safety, CAR-T persistence, and operational complexity all constrain real-world rollout in autoimmune populations.
Hengrui & Akeso (Chinese Multi-Mechanism Players)
Primary route: By contrast, hengrui leads with oral JAK family (Ivarmacitinib, Jaktinib) plus multiple antibody and small-molecule programs across autoimmune indications. Specifically, Akeso has multiple IL-17/IL-23 mAb approvals and developing bispecifics.
Key pipeline: Of course, hengrui has 14 autoimmune-related patents 2023+ across two corporate entities; Akeso has multiple NMPA-approved IL-17/IL-23 mAbs. Moreover, both companies are advancing oral peptide and bispecific programs.
Differentiation: Finally, pricing-led positioning and rapid NMPA approvals capture domestic Chinese share at scale. Furthermore, Chinese-developed oral chemistry has established differentiated cost-of-goods relative to Western mAbs.
Recent BD: Notably, multiple ex-China licensing discussions ongoing across both companies; Hengrui has executed several recent ex-China oncology deals that may extend into autoimmune indications.
Trajectory: Moreover, chinese players will continue to dominate domestic autoimmune share. As a result, the most credible global expansion stories will come via emerging-market licensing rather than US/EU launches.
Key risk: However, limited cardiovascular and long-term safety data versus established Western mAbs may constrain reimbursement in payer-driven markets.
Rome Therapeutics / Sitryx / Calico (Novel-Mechanism Platforms)
Primary route: In addition, rome Therapeutics targets transposable element / retroelement biology that drives interferon signaling in autoimmune disease; Sitryx focuses on immunometabolism modulators; Calico explores aging-related immune dysregulation. Specifically, all three target mechanisms outside the conventional cytokine and B-cell axes.
Key pipeline: As a result, rome has 4 patents 2023+ and multiple discovery-stage programs; Sitryx has 3 patents 2023+; Calico has 2 patents 2023+. Moreover, all three companies maintain academic and pharma partnerships.
Differentiation: Specifically, novel-mechanism platforms target the underlying drivers of autoimmunity rather than downstream cytokine effects, potentially providing disease-modifying or curative therapies. Furthermore, the platforms are mechanism-extensible across multiple indications.
Recent BD: Meanwhile, rome has pharma partnerships in multiple stages; Sitryx and Calico maintain VC and pharma collaborations.
Trajectory: In contrast, discovery to early clinical-stage. Validation depends on Phase 1/2 readouts of lead programs in 2026-2028.
Key risk: Similarly, mechanism-to-clinical translation gaps remain wide for novel autoimmune mechanisms; preclinical efficacy does not guarantee clinical relevance.
BD Deals & Strategic Moves
Deal Timeline
| Date | Deal | Parties | Type | Significance |
|---|---|---|---|---|
| 2026-04 | Anbalcabtagene autoleucel approval | Chinese sponsor | Regulatory | First CAR-T approval for autoimmune disease |
| 2025-11 | Puzolcabtagene autoleucel approval | Chinese sponsor | Regulatory | Second autoimmune CAR-T approval |
| 2025-08 | Tolebrutinib FDA approval | Sanofi | Regulatory | First BTK inhibitor for relapsing MS |
| 2025-09 | Remibrutinib FDA approval | Novartis | Regulatory | BTK for chronic spontaneous urticaria |
| 2025-11 | Sibeprenlimab IgAN approval | Visterra/Otsuka | Regulatory | APRIL antagonist for IgA nephropathy |
| 2024-Q3 | Sana hypoimmune CAR-T autoimmune trials | Sana Biotechnology | Trial | Hypoimmune CD19 CAR-T in lupus enrollment |
| 2023-Q4 | Cabaletta CABA-201 advancement | Cabaletta Bio | Trial | Multiple Phase 1/2 autoimmune cohorts |
Strategic Pattern
Notably, the BD landscape signals premium valuations for novel autoimmune mechanisms — with BTK, FcRn, APRIL, and CAR-T attracting the largest deals. Furthermore, autoimmune CAR-T’s Chinese-led approvals validate the modality and create pressure for Western regulatory engagement. However, traditional cytokine-targeted licensing has slowed, suggesting the field has internalized the maturity of the mAb route and now invests in mechanism diversification.
Unmet Needs & White Spaces
Opportunity Matrix
| Unmet Need | Current Approaches | Gap | White Space |
|---|---|---|---|
| Refractory autoimmune disease (curative) | Autologous & allogeneic CAR-T | Limited approved options outside China | Hypoimmune CAR-T, in vivo CAR-T, gene therapy |
| Progressive multiple sclerosis | Tolebrutinib, ocrelizumab | Limited disease-modifying therapy | CNS-penetrant BTK, microglial modulators |
| Pediatric autoimmune disease | Limited pediatric labels | Most products restricted to adults | Pediatric-specific dosing and formulations |
Risks and Strategic Outlook for 2026 and Beyond
Key Risks
- Notably, biosimilar entry of major IL-17, IL-23, TNF, and B-cell biologics from late 2020s will compress pricing across the entire injectable biologic class, eroding the franchise that has subsidized continued investment in autoimmune innovation.
- Moreover, oral biologic competition (Icotrokinra, Sotyktu, BTK inhibitors) is reshaping the moderate-to-severe segment, potentially eroding mAb commercial positioning faster than current trajectories imply.
- However, autoimmune CAR-T faces lymphodepletion safety, persistence, and operational scale challenges that may limit broad adoption outside specialist centers.
- In addition, payer pressure on multi-billion biologic spending may force reimbursement restrictions favoring lower-cost oral and biosimilar alternatives.
Strategic Outlook
Overall, autoimmune diseases have crossed from a competitive innovation phase anchored by cytokine biologics into a multi-modality phase including BTK, CAR-T, FcRn, APRIL antagonism, and emerging novel-mechanism platforms. Furthermore, the next 24 to 36 months will be defined by Tolebrutinib and Remibrutinib launch dynamics, autoimmune CAR-T regulatory engagement in Western markets, and the maturation of platform-level competition between Sana, Cabaletta, Rome, Sitryx, and Calico. Meanwhile, Chinese players will continue to dominate the bispecific and oral chemistry routes, with the most credible global partnerships likely to come through ex-China licensing.
If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.
Turn Complex Data into Decision-Ready Insights
Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.
- ✔ Domain-specific research Q&A
- ✔ Patent & literature analysis (2 files per upload)
- ✔ Lead compound analysis with SAR extraction (5 runs)
- ✔ 2 AI-powered Pulse briefs for early signals
